Amphotericin B, fluconazole, and nystatin as development inhibitors of Candida albicans biofilms on a dental prosthesis reline material: Analytical models in vitro.

STATEMENT OF PROBLEM: The use of antifungals has been suggested during the treatment of denture stomatitis associated with Candida albicans biofilms. However, how time, material surface, and substrates present during adhesion and biofilm development can influence clinical treatment is unclear. PURPOSE: The purpose of this in vitro study was to investigate the growth kinetics of C. albicans biofilms on surfaces of specimens under the influence of adsorbed films and to evaluate the antibiofilm efficacy of antifungal agents: amphotericin B, fluconazole, and nystatin. MATERIAL AND METHODS: Specimens of Silagum-Comfort Soft Relining were submerged in preconditioning systems: phosphate-buffered saline, artificial saliva, fetal bovine serum, and artificial saliva+fetal bovine serum. Planktonic cells were incubated (phosphate-buffered saline+specimens) for 1.5 hours (adhesion phase) and washed with phosphate-buffered saline solution. The specimens were then incubated (YNB+glucose) for 8, 24, and 48 hours (initial, intermediate, and maturation phases). The biofilm sessile minimum inhibitory concentration was determined by the broth microdilution method (7.81 to 500 µg/mL). The metabolic activity of the biofilms was tested by colorimetric assay (cell metabolic activity). Cell viability, relative biomass (µm3), and the thickness of the biofilm (µm) were evaluated by confocal laser scanning microscopy. RESULTS: The highest bioactivity was recorded in the presence of fetal bovine serum. Biofilms treated with fluconazole and amphotericin B were partially inhibited in a dose-dependent manner. Nystatin inhibited metabolic activity mainly from ≥15.63 or 62.5 µg/mL. Variations in magnitude parameters (relative biomass and thickness) were observed depending on the development phases of biofilms, whereas biological parameters (percentage of nonviable cells) were constant throughout the formation of C. albicans biofilms. CONCLUSIONS: The data suggest that partial (fluconazole and amphotericin B) or more effective (nystatin) reduction of metabolic activity of C. albicans biofilms occurred depending on the time and the antifungal and its concentrations.

Incidence of Shiga toxin-producing Escherichia coli in diarrheic calves and its susceptibility profile to antimicrobials and Eugenia uniflora L.

The aim of this study was to evaluate the occurrence of Shiga toxin (stx)-producing Escherichia coli (STEC) in diarrheic newborn calves, as well as the resistance profile of this microorganism against antimicrobials routinely used in veterinary therapy. The antimicrobial profile of Eugenia uniflora against E. coli clinical isolates was also analyzed. Specimens from the recto-anal junction mucosa were investigated by using chromogenic medium and identification of E. coli was done using microbiological methods (Gram staining, indole test, methyl red test, Voges-Proskauer test, citrate test, urease test, and hydrogen sulfide test). The stx1 and stx2 genes corresponding to the STEC pathotype were evaluated by using polymerase chain reaction and electrophoresis. The susceptibility profile to antimicrobial agents commonly used in veterinary therapeutic practice and the antimicrobial effect of lyophilized hydroalcoholic extract of E. uniflora L. leaves against E. coli clinical isolates were evaluated by disk diffusion and microdilution methods. Shiga toxin-positive E. coli was identified in 45% of diarrheic newborn calves (stx1 = 23.2%, stx2 = 4.0%, stx1 + stx2 = 18.2%). The frequency of stx-positive E. coli in the bacterial population was equal to 17.0% (168/990 clinical isolates): 97 (9.8%) stx1-positive E. coli, 12 (1.2%) stx2-positive E. coli, and 59 (6.0%) stx1 + stx2-positive E. coli isolates. All stx-positive E. coli analyzed showed resistance to multiple drugs, that is, from 4 to 10 antimicrobials per clinical isolate (streptomycin, tetracycline, cephalothin, ampicillin, sulfamethoxazole + trimethoprim, nitrofurantoin and nalidixic acid, ciprofloxacin, gentamicin, and chloramphenicol). Effective management measures should be implemented, including clinical and laboratory monitoring, in order to promote animal and worker health and welfare, prevent and control the spread of diseases, and ensure effective treatment of infectious diseases. The E. uniflora L. leaves showed inhibition of microbial growth based on the diameter of halos, ranging from 7.9 to 8.0 mm and 9.9 to 10.1 mm for concentrations of 50 and 150 mg/mL, respectively. This plant displayed bacteriostatic action and a minimum inhibitory concentration of 12.5 mg/mL for all clinical isolates. Its clinical or synergistic effects with antimicrobial agents must be determined from clinical and preclinical trials.

Le but de cette étude était d'évaluer la présence d'Escherichia coli (STEC) productrices de Shiga toxine (stx) chez les veaux nouveaunés diarrhéiques, ainsi que le profil de résistance de ce microorganisme aux antimicrobiens couramment utilisés en thérapie vétérinaire. Le profil antimicrobien d'Eugenia uniflora contre les isolats cliniques d'E. coli a également été analysé. Des échantillons de la muqueuse de la jonction recto-anale ont été étudiés en utilisant un milieu chromogène et l'identification d'E. coli a été effectuée à l'aide de méthodes microbiologiques (coloration de Gram, test à l'indole, test au rouge de méthyle, test de Voges-Proskauer, test de citrate, test d'uréase et production de sulfure d'hydrogène). Les gènes stx1 et stx2 correspondant au pathotype STEC ont été évalués en utilisant la réaction en chaîne par polymérase et l'électrophorèse. Le profil de sensibilité aux agents antimicrobiens couramment utilisés dans la pratique thérapeutique vétérinaire et l'effet antimicrobien de l'extrait hydroalcoolique lyophilisé de feuilles d'E. uniflora L. contre les isolats cliniques d'E. coli ont été évalués par des méthodes de diffusion en disque et de microdilution. Des E. coli positifs à la Shiga toxine ont été identifiés chez 45 % des veaux nouveau-nés diarrhéiques (stx1 = 23,2 %, stx2 = 4,0 %, stx1 + stx2 = 18,2 %). La fréquence des E. coli stx-positifs dans la population bactérienne était égale à 17,0 % (168/990 isolats cliniques) : 97 (9,8 %) E. coli positifs pour stx1, 12 (1,2 %) E. coli positifs pour stx2, et 59 isolats d'E. coli positifs pour stx1 + stx2 (6,0 %). Tous les E. coli stx positifs analysés ont montré une résistance à plusieurs médicaments, à savoir de 4 à 10 antimicrobiens par isolat clinique (streptomycine, tétracycline, céphalothine, ampicilline, sulfaméthoxazole + triméthoprime, nitrofurantoïne et acide nalidixique, ciprofloxacine, gentamicine et chloramphénicol). Des mesures de gestion efficaces devraient être mises en oeuvre, y compris une surveillance clinique et de laboratoire, afin de promouvoir la santé et le bien-être des animaux et des travailleurs, de prévenir et de contrôler la propagation des maladies et de garantir un traitement efficace des maladies infectieuses. Les feuilles d'E. uniflora L. ont montré une inhibition de la croissance microbienne basée sur le diamètre des zones, allant de 7,9 à 8,0 mm et de 9,9 à 10,1 mm pour des concentrations de 50 et 150 mg/mL, respectivement. Cette plante a montré une action bactériostatique et une concentration inhibitrice minimale de 12,5 mg/mL pour tous les isolats cliniques. Ses effets cliniques ou synergiques avec les agents antimicrobiens doivent être déterminés à partir d'essais cliniques et précliniques.(Traduit par Docteur Serge Messier).

Talinumpaniculatum: a plant with antifungal potential mitigates fluconazole-induced oxidative damage-mediated growth inhibition of Candida albicans / Talinum paniculatum: una planta con potencial antifúngico atenúa la inhibición del crecimiento de Candida albicans mediada por el daño oxidativo inducido por fluconazol

SUMMARY Aims: This study investigated the bioactivity of the crude leaf extract (CLE) and fractions hexane (HX) and ethyl acetate (EtOAc) from Talinum paniculatum alone and in association with fluconazole (FLC) against reference strain and clinical isolates of FLC-resistant Candida albicans. Furthermore, the antioxidant capability, chemical composition of this plant, and the effect's underlying mechanisms were evaluated. Methods: The antifungal activity was evaluated using checkerboard assay to establish the minimum inhibitory (MIC) and minimum microbicidal concen trations (MMC). During FLC and plant products challenges, the reactive oxygen species (ROS) generation (hydroxyl radicals [HO●]) were detected in C. albicans cells using the membrane-permeable fluorescent probes APF and HPF. High-performance liquid chromatography (HPLC) profile, quantitative analysis of antioxidant compounds, and free radical scavenging activity (DPPH assay) tests were performed. Results: The CLE and fractions presented outstanding antifungal activity and selectivity against C. albicans cells but had no synergistic effect's with FLC. The MIC values for CLE and its fractions against C. albicans reference strain were in the order of HX (31.25 µg ml-1) < EtOAc (62.5 μg ml-1) < CLE (500 μg ml-1), and against FLC-resistant C. albicans HX (125 μg ml-1) = EtOAc < CLE (500 μg ml-1). CLE and its fractions had more potent antifungal activities than FLC against the clinical isolates. Moreover, fungicidal effect's for these plant products were demonstrated against FLC-resistant C. albicans, which further conirmed an antifungal potential. Conversely, during association, plant products were shown to cause an increase in FLC MIC anywhere from 2- to 16-fold. FLC exposure led to an increase in the steady-state levels of ROS (HO●) in C. albicans cells. Next, we found that the increases in FLC MICs were owing to action of antioxidants containing-CLE and its fractions in preventing FLC-induced ROS-mediated growth inhibition of C. albicans. Conclusion: T. paniculatum can be a source of bioactive compounds with antifungal potential. However, because of the common use of its edible leaf, caution is advised during therapy with FLC (since it can decrease FLC susceptibility).

RESUMEN Objetivos: este estudio investigó la bioactividad del extracto de hoja en bruto (EHB) y las fracciones hexano (HX) y acetato de etilo (AcOEt) de Talinum paniculatum solo y en asociación con fluconazol (FLC) contra cepas de referencia y aislados clínicos de Candida albicans resistente a FLC. Además, evaluó la capacidad antioxidante, la composición química de esta planta y los mecanismos subyacentes del efecto fungicida. Métodos: la actividad antifúngica se evaluó mediante microdilución en caldo para establecer las concentraciones inhibitorias mínimas (CIM) y microbicidas mínimas (CMM). Durante el tratamiento con FLC y productos vegetales se detectó la generación de especies reactivas de oxígeno (ERO) (radicales hidroxilo [HO●]) en células de C. albicans utilizando las sondas fluorescentes permeables a la membrana APF y HPF. El perfil de cromatografía líquida de alta resolución (CLAR), el análisis cuantitativo de compuestos antioxidantes y el ensayo DPPH fueron evaluados. Resultados: el EHB y las fracciones presentaron una excelente actividad antifúngica y selectividad contra las células de C. albicans, pero no tuvieron efectos sinérgicos con FLC. Los valores de CIM para EHB y sus fracciones contra la cepa referencia de C. albicans fueron del orden de: HX (31,25 μg ml-1) < AcOEt (62,5 μg ml-1) < EHB (500 μg ml-1), y contra C. albicans resistente a FLC: HX (125 μg ml-1)= AcOEt < EHB (500 µg ml-1). EHB y sus fracciones fueron más potentes antifúngicos que FLC contra los aislados clínicos. Además, estos productos vegetales tienen efectos fungicidas contra C. albicans resistentes a FLC, esto conirmó el potencial antifúngico. Por el contrario, durante la asociación se demostró que los productos vegetales causan un aumento en la CIM de FLC de 2 a 16 veces. La exposición a FLC aumentó los niveles de ERO (HO●) en las células de C. albicans. Los aumentos en las CIM de FLC se debieron a la acción de los antioxidantes presentes en EHB y sus fracciones para prevenir la inhibición del crecimiento mediada por ERO inducida por FLC en C. albicans. Conclusión: T. paniculatum puede ser una fuente de compuestos bioactivos con potencial antifúngico. Sin embargo, debido al uso común de su hoja comestible, se recomienda usarla con precaución durante la terapia con FLC (ya que puede disminuir la susceptibilidad a FLC).

Talinum paniculatum leaves with in vitro antimicrobial activity against reference and clinical strains of Staphylococcus aureus interfere with oxacillin action / Las hojas de Talinum paniculatum con actividad antimicrobiana in vitro contra cepas de referencia y clínicas de Staphylococcus aureus interfieren con la acción de la oxacilina

SUMMARY Propose: We evaluated the antibacterial potential of the crude leaf extract (CLE) and fractions hexane (HX) and ethyl acetate (EtOAc) from Talinum paniculatum alone and in association with oxacillin (OXA) against OXA-resistant Staphylococcus aureus (ORSA, environment isolates) and OXA-sensitive S. aureus (OSSA, ATCC 25923). Furthermore, toxicity tests were performed. Methods: The antibacterial activity was evaluated through checkerboard assay (broth microdilution) to establish the minimum inhibitory (MIC) and minimum bactericidal concentrations (MBC). Toxicity test in mice was assessed. Results: The MIC values for the CLE and its fractions against ORSA and OSSA were in the order of HX (500 μg ml-1) = EtOAc < CLE (4000 μg ml-1). EtOAc and HX presented outstanding antibacterial activities against ORSA, and these fractions were bactericidal toward OSSA. Conversely, the associations between plant product (CLE, EtOAc, or HX) and OXA exhibited no synergistic effects. During these associations, there was an increase in OXA MICs anywhere from 2- to 4092-fold. The CLE presented absence of toxicity at a dose of 5 g kg-1 (in vivo). Conclusion: Although T. paniculatum be a good source of bioactive compounds with antistaphylococcal potential, the researchers should be cautious, since its edible leaf may interfere with OXA therapy (mitigating OXA-induced growth inhibition or killing of S. aureus and enhancing S. aureus resistance).

RESUMEN Propósito: evaluamos el potencial antibacteriano del extracto de hoja en bruto (EHB) y las fracciones hexano (HX) y acetato de etilo (AcOEt) de Talinum paniculatum solo y en asociación con oxacilina (OXA) contra Staphylococcus aureus resistente a OXA (ORSA, ambientales) y S. aureus sensible a OXA (OSSA, ATCC 25923). Además, se realizaron pruebas de toxicidad. Métodos: la actividad antibacteriana se evaluó mediante microdilución en caldo para establecer las concentraciones inhibitorias mínimas (CIM) y bactericidas mínimas (CBM). Se evaluó la toxicidad en ratones. Resultados: los valores de CIM para el EHB y sus fracciones contra ORSA y OSSA fueron del orden de HX (500 μg ml-1) = AcOEt < EHB (4000 μg ml-1). AcOEt y HX presentaron actividades antibacterianas sobresalientes contra ORSA, y estas fracciones fueron bactericidas hacia OSSA. Por el contrario, las asociaciones entre el producto vegetal (EHB, AcOEt o HX) y OXA no mostraron efectos sinérgicos. Durante estas asociaciones, hubo un aumento en las CIM de OXA de 2 a 4092 veces. EHB no mostró toxicidad a una dosis de 5 g kg-1. Conclusión: aunque T. paniculatum es una buena fuente de compuestos bioactivos con potencial antiestofilocócico, los investigadores deben ser cautelosos, ya que su hoja comestible puede interferir con la terapia con OXA (mitigando la inhibición del crecimiento inducida por OXA o la muerte de S. aureus y promoviendo resistencia bacteriana).

Genetic diversity and exoenzyme activities of Candida albicans and Candida dubliniensis isolated from the oral cavity of Brazilian periodontal patients.

OBJECTIVE: Mucosal surfaces are the primary oral reservoirs of Candida species, but these species can also be found in subgingival biofilm. The present study investigated the genetic diversity and production of exoenzymes of C. albicans and C. dubliniensis isolated from the oral cavity of systemically healthy patients with periodontitis. DESIGN: Fifty-three patients were analysed. Samples were collected from three oral cavity sites (periodontal pocket, gingival sulci and oral mucosa), plated and, after isolation, suspect strains of C. albicans and C. dubliniensis were identified by PCR. The genetic diversity of the isolates was evaluated by RAPD and the activities of the secreted aspartyl proteinases and phospholipases were evaluated by the agar plate method. RESULTS: Twenty-one patients showed positive results for Candida spp. There were no statistically significant differences between genders, or between sites. C. albicans was the most frequently found specie, while C. dubliniensis was isolated from the periodontal pocket of only one patient. Sixteen genotypes were detected among the C. albicans isolates, and one among the C. dubliniensis isolates. The similarity coefficient (S(SM)) values among the C. albicans genotypes ranged from 0.684 to 1.0 with an average of 0.905+/-0.074. All isolates produced high levels of Saps and most of them produced high levels of phospholipases. No relationship was found between the genotypes and the pattern of enzymatic production. There was no association between specific genotypes and their site of isolation. CONCLUSIONS: The results of the present study suggest that genetically homogeneous strains of C. albicans are present in the oral cavity of patients with periodontitis and that these strains are capable of producing high levels of exoenzyme.